Name | (2S,3R,4R,5S,6R)-2-[5-[(4-ethoxyphenyl)methyl]-2-methoxy-4-methylphenyl]-6-(hydroxymethyl)thiane-3,4,5-triol |
---|---|
Synonyms |
TS-071
Luseogliflozin Lusefi (1S)-1,5-Anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol D-Glucitol, 1,5-anhydro-1-C-[5-[(4-ethoxyphenyl)methyl]-2-methoxy-4-methylphenyl]-1-thio-, (1S)- UNII-C596HWF74Z TS-71 TS 071 |
Description | Luseogliflozin (TS 071) is a potent, selective, orally active sodium-dependent glucose cotransporter (SGLT) 2 inhibitor, with an IC50 of 2.26 nM, about 1765-fold selectivity over SGLT1 (IC50, 3990 nM). Luseogliflozin has the protential for treating type 2 diabetes. |
---|---|
Related Catalog | |
Target |
SGLT2:2.26 nM (IC50) SGLT1:3990 nM (IC50) |
In Vitro | Luseogliflozin (TS-071, 3p) is a potent sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor, with an IC50 of 2.26 nM, about 1765-fold selectivity over SGLT1 (IC50, 3990 nM); Luseogliflozin has the protential for treating type 2 diabetes[1]. |
In Vivo | Luseogliflozin (1 mg/kg, p.o.) exhibits a blood glucose lowering effect, excellent urinary glucose excretion properties, and promising PK profiles in rats and dogs[1]. |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 624.5±55.0 °C at 760 mmHg |
Melting Point | 155.0-157.0℃ |
Molecular Formula | C23H30O6S |
Molecular Weight | 434.546 |
Flash Point | 331.5±31.5 °C |
Exact Mass | 434.176300 |
PSA | 124.68000 |
LogP | 4.43 |
Vapour Pressure | 0.0±1.9 mmHg at 25°C |
Index of Refraction | 1.616 |